This synthesis page documents the complete causal chain from PSEN2 (Presenilin 2) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points. PSEN2 is the second causative gene for familial Alzheimer's disease and provides unique insights into gamma-secretase biology and disease heterogeneity.
PSEN2 encodes Presenilin 2, the catalytic subunit of the gamma-secretase complex. While less frequently mutated than PSEN1, PSEN2 mutations cause both familial and potentially sporadic Alzheimer's disease.
| Property |
Value |
| Chromosome |
1q42.13 |
| Protein |
Presenilin 2 (448 amino acids) |
| Function |
Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance |
Autosomal dominant |
| Age of Onset |
Typically 55-75 years (mean ~65) |
Over 70 pathogenic mutations in PSEN2 have been identified. The most well-characterized include:
| Mutation |
Location |
Effect |
Population |
| N141I |
TM2 |
Severe Aβ42 increase, reduced activity |
Volga German |
| M239V |
TM6 |
Increased Aβ42/Aβ40 ratio |
Italian |
| T122P |
TM4 |
Impaired gamma-secretase |
German |
| M239I |
TM6 |
Altered APP processing |
- |
| A85V |
TM2 |
Partial loss of function |
- |
| R62H |
TM1 |
Reduced proteolytic activity |
- |
- Causality strength: Absolutely proven - PSEN2 mutations are fully penetrant causes of familial AD
- Population frequency: Very rare (<0.001% of population)
- Age of onset: Later than PSEN1 (~65 years average), consistent with "late-onset" FAD
- Segregation: Perfect Mendelian inheritance in affected families
- Unique feature: Some PSEN2 mutations show incomplete penetrance or variable expressivity
PSEN2 functions as the catalytic core of the gamma-secretase complex, similar to PSEN1 but with distinct biochemical properties:
flowchart TD
A["APP protein"] --> B["Alpha-secretase"]
A --> C["Beta-secretase BACE1"]
B --> D["sAPPα"]
C --> E["C99 fragment"]
E --> F["Gamma-secretase<br/>PSEN2-containing complex"]
F --> G["APH1"]
F --> H["PEN2"]
F --> I["Nicastrin"]
G --> J["Aβ peptides"]
J --> K["Aβ40"]
J --> L["Aβ42"]
J --> M["Aβ43"]
L --> N["Plaque formation"]
M --> N
PSEN2-containing γ-42 complexes differ from PSEN1 complexes in several ways:
- Substrate affinity - PSEN2 shows different substrate preferences
- Cleavage efficiency - Generally lower overall catalytic activity
- Aβ profile - Tends to produce more Aβ43 in addition to Aβ42
- Cellular distribution - More abundant in non-neuronal tissues
PSEN2 mutations alter gamma-secretase cleavage through multiple mechanisms:
flowchart TD
A["PSEN2 mutation"] --> B["Altered gamma-secretase activity"]
B --> C["Shifted Aβ42/Aβ40 ratio"]
B --> D["Reduced overall proteolysis"]
B --> E["Altered cleavage position"]
C --> F["Aβ42 oligomerization"]
D --> G["ER stress"]
E --> H["Aβ43 production"]
F --> I["Synaptic toxicity"]
G --> J["Calcium dysregulation"]
H --> K["Plaque nucleation"]
I --> L["Cognitive decline"]
J --> L
K --> L
- Increased Aβ42/Aβ40 ratio - Most PSEN2 mutations increase the proportion of longer, aggregation-prone Aβ peptides
- Aβ43 production - Some PSEN2 mutations produce elevated Aβ43, even more aggregation-prone than Aβ42
- Partial loss-of-function - Paradoxically, many PSEN2 mutations reduce overall gamma-secretase activity while increasing Aβ42 proportion
- ER calcium dysregulation - Mutant PSEN2 affects calcium homeostasis through ER-mitochondria contacts
PSEN2 has unique roles in mitochondrial biology not shared with PSEN1:
flowchart LR
subgraph Direct Effects
A["PSEN2 mutation"] --> B["Mitochondrial PSEN2"]
B --> C["Complex I dysfunction"]
B --> D["Import channel alteration"]
B --> E["Dynamin-like protein 1 abnormal"]
end
subgraph Indirect Effects
F["Aβ42"] --> C
G["Calcium dysregulation"] --> H["Mitochondrial Ca2+ overload"]
H --> I["ATP depletion"]
end
C --> I
D --> I
E --> J["Mitochondrial fragmentation"]
I --> K["Neuronal death"]
J --> K
¶ Autophagy and Lysosomal Dysfunction
PSEN2 mutations impair autophagy through multiple mechanisms:
- Autophagosome accumulation - Reduced fusion with lysosomes
- Lysosomal acidification defect - Impaired protease activity
- TFEB nuclear translocation - Reduced autophagy gene expression
- mTORC1 dysregulation - Altered nutrient sensing
PSEN2 mutations contribute to synaptic failure through:
- Aβ-induced LTP impairment - Memory trace weakening
- Calcium dysregulation - ER calcium leak through mutant presenilin
- Synaptic protein trafficking - Altered delivery to synapses
- Mitochondrial energy deficit - Insufficient ATP for synaptic function
| Stage |
Age |
Clinical Features |
| Preclinical |
55-60 |
Normal cognition, biomarker changes (elevated Aβ42, tau) |
| Prodromal |
60-65 |
MCI, episodic memory deficits |
| Mild AD |
65-70 |
Working memory impairment, word-finding difficulty |
| Moderate AD |
70-75 |
Disorientation, behavioral changes |
| Severe AD |
75+ |
Global cognitive decline, motor symptoms |
PSEN2 mutations show distinct clinical features from PSEN1:
- Later age of onset - Average ~65 years vs ~45 years for PSEN1
- Atypical presentations - Some mutations cause spastic paraparesis
- Variable penetrance - Some PSEN2 mutations show incomplete penetrance
- Pathology diversity - Some cases show Lewy body co-pathology
- Psychiatric symptoms - Higher frequency of depression and psychosis
| Feature |
PSEN1 |
PSEN2 |
| Age of onset |
30-60 years |
55-75 years |
| Disease duration |
8-12 years |
10-15 years |
| Myoclonus/seizures |
Common |
Less common |
| Spastic paraparesis |
Rare |
Some mutations |
| Atypical features |
Less common |
More common |
| Intervention |
Mechanism |
Development Stage |
Target |
| Gamma-secretase modulators (GSMs) |
Shift cleavage to less Aβ42 |
Phase 2/3 |
Aβ42 production |
| Anti-Aβ antibodies |
Passive immunization |
Phase 3 (lecanemab, donanemab) |
Aβ plaques |
| Aβ oligomer inhibitors |
Block toxic oligomers |
Preclinical |
Aβ42 oligomers |
| Notch-sparing inhibitors |
Reduce Notch side effects |
Preclinical |
γ-secretase |
| PSEN2-selective modulators |
Target PSEN2 complexes |
Preclinical |
PSEN2-γ42 |
- Later age of onset - Longer therapeutic window for prevention
- Incomplete penetrance - Potential for early intervention in carriers
- Mitochondrial effects - Additional targets beyond Aβ
- Lower Notch impact - PSEN2 complexes may have different Notch involvement
| Approach |
Strategy |
Challenges |
Timeline |
| ASO therapy |
Silence mutant PSEN2 |
Allele-specific targeting |
5-10 years |
| CRISPR-Cas9 |
Correct mutation |
CNS delivery, efficiency |
10+ years |
| Protein folding drugs |
Correct PSEN2 misfolding |
Brain delivery |
5-10 years |
| Mitochondrial protectants |
Restore mitochondrial function |
Target mitochondria |
3-7 years |
flowchart TD
subgraph Prevention
A["PSEN2 mutation carriers"] --> B["Lifestyle intervention"]
A --> C["Biomarker monitoring"]
A --> D["Early detection"]
end
subgraph Disease Modification
B --> E["GSMs"]
C --> F["Anti-Aβ immunotherapy"]
D --> G["Preclinical intervention"]
E --> H["Reduce Aβ42"]
F --> I["Clear plaques"]
G --> J["Neuroprotection"]
end
subgraph Symptomatic
H --> K["Slow progression"]
I --> K
J --> K
end
style A fill:#ffcdd2
style K fill:#c8e6c9
| Category |
Score |
Rationale |
| Genetic Causality |
10/10 |
Fully penetrant, autosomal dominant, >70 mutations identified |
| Mechanism Validation |
9/10 |
Gamma-secretase complex well-characterized, distinct PSEN2 properties |
| Therapeutic Potential |
7/10 |
Multiple approaches in development; later onset provides longer window |
| Clinical Translation |
7/10 |
Biomarkers available but less clinical trial data than PSEN1 |
| Overall |
8.25/10 |
Strong evidence for causal chain with unique features |
- Late-onset familial AD: PSEN2 accounts for ~5-10% of FAD cases
- Sporadic AD modifier: PSEN2 variants may modify risk in LOAD
- Atypical AD: Some PSEN2 mutations cause posterior cortical atrophy or spastic paraparesis
| Disease |
Connection |
Evidence |
| Parkinson's Disease |
PSEN2 affects alpha-synuclein processing; mitochondrial complex I |
Moderate |
| FTD |
TDP-43 co-pathology in some cases |
Weak-Moderate |
| ALS |
Shared neuroinflammation pathways |
Weak |
| Cerebral amyloid angiopathy |
Aβ42 vascular deposition |
Strong |
- Protein aggregation - Similar to α-synuclein (PD), TDP-43 (ALS)
- Mitochondrial dysfunction - Universal feature across neurodegenerative diseases
- ER stress - Shared with ALS (C9orf72, SOD1)
- Autophagy impairment - Common across AD, PD, ALS
| Feature |
PSEN1 |
PSEN2 |
| Mutation count |
300+ |
70+ |
| Age of onset |
30-60 years |
55-75 years |
| Expression pattern |
Ubiquitous |
More restricted |
| Aβ profile |
Aβ42 ↑↑ |
Aβ42/Aβ43 ↑ |
| Mitochondrial role |
Less prominent |
Prominent |
| Notch processing |
Primary |
Secondary |
¶ Knowledge Gaps and Research Priorities
- Mechanism heterogeneity - Why do different PSEN2 mutations cause different phenotypes?
- Non-amyloid functions - What are the non-gamma-secretase roles of PSEN2 in neurons?
- Incomplete penetrance - What genetic modifiers affect PSEN2 mutation expression?
- PSEN2 vs PSEN1 - Why does PSEN2 cause later-onset disease?
- Therapeutic targeting - How to selectively modulate PSEN2-containing complexes?
| Priority |
Research Area |
Rationale |
| 1 |
PSEN2-selective GSMs |
Target PSEN2-containing complexes specifically |
| 2 |
Mitochondrial protectants |
Exploit unique PSEN2 mitochondrial roles |
| 3 |
Biomarker development |
Earlier detection in PSEN2 carriers |
| 4 |
Gene therapy |
Direct correction of pathogenic mutations |